NYU Doctors Explain DCIS

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.